Literature DB >> 17394012

Acceptance of neoadjuvant short-term radiotherapy: a survey under surgeons and radiotherapists.

Alexis Ulrich1, Jessica Schwerdt, Kaspar Z'graggen, Peter Kienle, Jürgen Weitz, Markus W Büchler.   

Abstract

BACKGROUND AND AIMS: Since introduction of total mesorectal excision (TME) the prognosis of rectal cancer patients has improved significantly. Debate exists regarding the optimal mode of multimodal treatment. The aim of this survey was to determine the preferred multimodal treatment and the significance and acceptance of short-term radiotherapy (5 x 5 Gy) in Germany.
METHODS: In August 2003, a questionnaire was sent to the heads of all 1,275 surgical and 157 radiotherapy departments in Germany.
RESULTS: Four hundred ninety-three of 1,275 surgical (39%) and 89 of 157 radiotherapeutic questionnaires (56%) were returned. The majority of the answering surgeons and radiotherapists performed adjuvant (89 and 100%), followed by neoadjuvant (61 and 94%) and short-term radiotherapy (5 x 5 Gy) (16 and 17%). Other questions of the survey dealt with indications for each treatment modality, the initiation of treatment, and reasons for objection to short term radiotherapy.
CONCLUSION: Short-tem radiotherapy played a minor role in the treatment of rectal cancer patients in 2003 and was mainly initiated by surgeons (approximately 70%). However, 74% of the answering surgeons and 42% of the answering radiotherapists not performing short-term radiotherapy in 2003 were open minded towards the introduction of this treatment modality.

Entities:  

Mesh:

Year:  2007        PMID: 17394012     DOI: 10.1007/s00423-006-0139-0

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  10 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.

Authors:  K Bujko; M P Nowacki; A Nasierowska-Guttmejer; W Michalski; M Bebenek; M Kryj
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

4.  Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Rectal Cancer Study Group.

Authors: 
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

5.  Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial.

Authors:  C A M Marijnen; E Kapiteijn; C J H van de Velde; H Martijn; W H Steup; T Wiggers; E Klein Kranenbarg; J W H Leer
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

6.  Recurrence and survival after total mesorectal excision for rectal cancer.

Authors:  R J Heald; R D Ryall
Journal:  Lancet       Date:  1986-06-28       Impact factor: 79.321

7.  Late adverse effects of short-course preoperative radiotherapy in rectal cancer.

Authors:  J Pollack; T Holm; B Cedermark; D Altman; B Holmström; B Glimelius; A Mellgren
Journal:  Br J Surg       Date:  2006-12       Impact factor: 6.939

8.  Prognostic factors of rectum carcinoma--experience of the German Multicentre Study SGCRC. German Study Group Colo-Rectal Carcinoma.

Authors:  P Hermanek; H Wiebelt; D Staimmer; S Riedl
Journal:  Tumori       Date:  1995 May-Jun       Impact factor: 2.098

Review 9.  [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status].

Authors:  C Rödel; W Hohenberger; R Sauer
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

  10 in total
  2 in total

1.  Modified neoadjuvant short-course radiation therapy in uT3 rectal carcinoma: low local recurrence rate with unchanged overall survival and frequent morbidity.

Authors:  Rainer Kube; Henry Ptok; David Jacob; Jörg Fahlke; Pawel Mroczkowski; Hans Lippert; Gunther Ziegenhardt; Uwe Schmidt; Ingo Gastinger
Journal:  Int J Colorectal Dis       Date:  2009-10-31       Impact factor: 2.571

2.  Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.

Authors:  Benjamin Garlipp; Henry Ptok; Uwe Schmidt; Frank Meyer; Ingo Gastinger; Hans Lippert
Journal:  Langenbecks Arch Surg       Date:  2010-08-15       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.